[144] Phibro Animal Health Corporation SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Phibro Animal Health Corporation (PAHC) indicating a proposed sale of 281,600 shares of Class A common stock through Goldman Sachs & Co. LLC on 09/04/2025. The filing lists an aggregate market value of $11,002,112 against 20,367,574 shares outstanding, and shows the securities were originally acquired on 04/14/2014 in a private placement from the issuer, with the consideration described as an exchange of securities. The filer reports no securities sold in the past three months and includes the standard representation that the selling person is not aware of undisclosed material adverse information.

Positive

• Complete Rule 144 fields provided: broker name, share count, aggregate market value, acquisition date and nature
• No securities sold in past three months: filing reports "Nothing to Report" for recent sales

Negative

• Proposed sale disclosed: 281,600 shares to be sold (aggregate value $11,002,112) which may dilute insider holdings
• Limited seller identification: form does not identify the specific selling person by name in the provided content

Insights

Securities Analyst

TL;DR: Proposed sale equals 1.38% of outstanding shares; routine Form 144 disclosure of previously privately placed shares.

The filing shows a notice to sell 281,600 Class A shares with an aggregate market value of $11,002,112. Using the disclosed outstanding share count, the proposed sale represents about 1.38% of outstanding stock, indicating a modest-sized disposition rather than a controlling divestiture. The use of a major broker (Goldman Sachs) and the prior acquisition via private placement are consistent with orderly disposition procedures under Rule 144. No recent sales in the prior three months are reported, which may indicate this is the first planned sale within the reporting window.

Compliance / Risk Analyst

TL;DR: Document is a standard Rule 144 notice that includes required acquisition and sale details and a certification about material non-public information.

The form contains the necessary elements for Rule 144 compliance: broker identification, number of shares, aggregate market value, acquisition date and nature (private placement), and statement regarding material adverse information. The filing also notes payment nature as an "exchange of securities." There are no indications in the document of trading-plan dates or other 10b5-1 specifics. From a compliance perspective, the filing appears to meet disclosure requirements but does not provide any information about the identity of the selling person beyond the acquisition counterparty.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	281600	11002112	20367574	09/04/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	04/14/2014	Private placement from issuer	Phibro Animal Health Corporation			281600	04/14/2014	Exchange of Securities

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the PAHC Form 144 disclose?

The filing discloses a proposed sale of 281,600 Class A shares through Goldman Sachs & Co. LLC with aggregate market value $11,002,112 and an intended sale date of 09/04/2025.

When were the shares being sold originally acquired?

The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation; payment is described as an exchange of securities.

How large is the proposed sale relative to outstanding shares?

Based on the disclosed outstanding share count of 20,367,574, the proposed sale of 281,600 shares represents approximately 1.38% of outstanding shares.

Does the filing report any sales in the past three months?

No. The filing section for securities sold during the past three months states "Nothing to Report".

Which broker will handle the sale?

The notice lists Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY, as the broker.